转移性去势抵抗性前列腺癌中紫杉烷类与新型雄激素靶向治疗的序贯方案:国际多中心回顾性CATS数据库结果
基于国际多中心回顾性CATS数据库669例转移性去势抵抗性前列腺癌患者,评估多西他赛、卡巴他赛与新型雄激素受体靶向药物三种序贯方案的疗效。结果显示卡巴他赛似乎不受序贯顺序影响而保持活性,雄激素受体靶向药物治疗后多西他赛活性可能降低,但数据不足以断定交叉耐药。
要点
- 卡巴他赛似乎无论治疗顺序如何均保持其活性
- 雄激素受体靶向药物治疗后多西他赛活性似乎降低,但数据不足以断定交叉耐药
- 三种序贯方案中从首次延长生存治疗算起的中位总生存期最高达35.8个月
核心结论
- 在这项回顾性试验中,多西他赛、卡巴他赛和一种雄激素受体靶向药物的序贯方案与中位总生存期最高达35.8个月相关。
- 卡巴他赛似乎无论治疗顺序如何均保持其活性。
- 雄激素受体靶向药物治疗后多西他赛活性似乎降低,但数据不足以断定交叉耐药。
研究设计与样本
- 国际多中心回顾性CATS数据库研究。
- 2012年11月至2016年10月期间回顾性收集669例连续转移性去势抵抗性前列腺癌患者数据。
- 患者按三种序贯方案分组:组1为多西他赛→卡巴他赛→雄激素受体靶向药物(158例),组2为多西他赛→雄激素受体靶向药物→卡巴他赛(456例),组3为雄激素受体靶向药物→多西他赛→卡巴他赛(55例)。
主要发现
- 基线时,仅PSA进展和Gleason评分<8在组3中更常见。
- 多西他赛的PSA应答在组3中低于其他组(p=0.02)。
- 卡巴他赛的PSA应答在二线治疗中高于三线治疗(p=0.001)。
- 组3中雄激素受体靶向药物的影像学无进展生存期为6.6个月、多西他赛为9.2个月,均短于其他组。
- 从首次延长生存治疗算起,组1、组2和组3的总生存期分别达到34.8个月、35.8个月和28.9个月(p=0.007)。
关键数值与推荐
- 主要终点为每种治疗的PSA应答(较基线下降≥50%)。
- 次要终点包括最佳临床获益、至PSA进展时间、影像学无进展生存期、总生存期和毒性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 该试验的主要局限性为回顾性设计。
- 组3患者数量少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The optimal sequence of life-extending therapies in metastatic castration-resistant prostate cancer (mCRPC) is unknown. OBJECTIVE: To evaluate outcomes among mCRPC patients treated with docetaxel (DOC), cabazitaxel (CABA), and a novel androgen receptor-targeted agent (ART; abiraterone acetate or enzalutamide) according to three different sequences. DESIGN, SETTING, AND PARTICIPANTS: Data from 669 consecutive mCRPC patients were retrospectively collected between November 2012 and October 2016. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint was the prostate-specific antigen (PSA) response (decrease ≥50% from baseline) to each therapy. Secondary endpoints included best clinical benefit, time to PSA progression, radiological progression-free survival (rPFS), overall survival (OS), and toxicity. RESULTS AND LIMITATIONS: A total of 158 patients received DOC→CABA→ART (group 1), 456 received DOC→ART→CABA (group 2), and 55 received ART→DOC→CABA (group 3). At baseline, PSA progression only and Gleason <8 were more common in group 3. PSA response on DOC was lower in group 3 than in other groups (p=0.02) and PSA response on CABA was higher in the second than in the third line (p=0.001). In Group 3, rPFS on ART (6.6 mo) and DOC (9.2 mo) was also shorter than in the other groups. OS calculated from the first life-extending therapy reached 34.8, 35.8, and 28.9 mo in groups 1, 2 and 3, respectively (p=0.007). Toxicity was comparable between the arms. The main limitations of the trial are its retrospective design and the low number of patients in group 3. CONCLUSIONS: In this retrospective trial, sequencing of DOC, CABA, and one ART, was associated with median OS of up to 35.8 mo. CABA seemed to retain its activity regardless of treatment sequence. DOC activity after ART appeared to be reduced, but the data are insufficient to conclude that cross-resistance occurs. PATIENT SUMMARY: The order of drugs administered to patients with metastatic castration-resistant prostate cancer could impact their efficacy, with cabazitaxel appearing to retain its activity whatever the therapeutic sequence.
引用
- Delanoy N, Hardy-Bessard AC, Efstathiou E, et al. Sequencing of Taxanes and New Androgen-targeted Therapies in Metastatic Castration-resistant Prostate Cancer: Results of the International Multicentre Retrospective CATS Database. Eur Urol Oncol. 2018. PMID: 31158090. doi:10.1016/j.euo.2018.05.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。